1. |
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin, 2009, 59(4): 225-249.
|
2. |
方积乾, 徐勇勇, 陈峰, 等. 卫生统计学. 7版. 北京: 人民卫生出版社, 2012: 419.
|
3. |
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125): 1023-1075.
|
4. |
Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol, 2016, 11(1): 39-51.
|
5. |
史国栋, 徐裕金, 孙晓江, 等. 转移性非小细胞肺癌患者不同生存期预后分析. 中国现代医生, 2013, 51(19): 10-12, 51.
|
6. |
Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer, 2014, 15(5): 346-355.
|
7. |
de Vin T, Engels B, Gevaert T, et al. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol, 2014, 25(2): 467-471.
|
8. |
Yang CJ, Gu L, Shah SA, et al. Long-term outcomes of surgical resection for stage Ⅳ non-small-cell lung cancer: a national analysis. Lung Cancer, 2018, 115: 75-83.
|
9. |
Collen C, Christian N, Schallier D, et al. Phase Ⅱ study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol, 2014, 25(10): 1954-1959.
|
10. |
De Ruysscher D, Wanders R, van BA, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase Ⅱ trial (Nct01282450). J Thorac Oncol, 2012, 7(10): 1547-1555.
|
11. |
Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol, 2014, 9(2): 154-162.
|
12. |
Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase Ⅲ, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 2011, 29(21): 2866-2874.
|
13. |
Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.
|
14. |
Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer, 2009, 115(8): 1723-1733.
|
15. |
Iyengar P, Kavanagh BD, Wardak Z, et al. Phase Ⅱ trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol, 2014, 32(34): 3824-3830.
|
16. |
王春英, 程明, 汪德文, 等. 吉非替尼联合同步放疗治疗 EGFR 突变型转移性非小细胞肺癌的疗效及安全性. 中国肿瘤临床与康复, 2017(11): 1324-1327.
|
17. |
汪丽, 谢金龙, 吴艳. 吉非替尼靶向介导在 sIMRT 治疗非小细胞肺癌中的应用分析. 临床肺科杂志, 2015, 20(8): 1377-1379, 1384.
|
18. |
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer. N Engl J Med, 2017, 377(20): 1919-1929.
|
19. |
Shaverdian N, Lisberg AE, Bornazyan KA, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol, 2017, 18(7): 895-903.
|